Navigation Links
Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
Date:8/11/2009

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine((R)). The Company has an NDA under review with the FDA for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). Triapine((R)), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible delays in the FDA's review process beyond our expectation for approval in December 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations or to enter into strategic partnership agreements, the inability to access capital and funding on favorable terms, continued operating losses an
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 The biggest name in indoor ... the world’s first fully integrated air quality platform that ... an air purifier to remove dust, pollen and hazardous ... control, via phone, tablet or computer. , Sweden’s Blueair, ... countries worldwide, will unveil its Internet-enabled air sensor together ...
(Date:3/3/2015)... SC (PRWEB) March 03, 2015 The ... the public’s expectation of excellence in care and safe ... the position of the RNS that biologic infusions are ... under the direct supervision of a registered nurse (RN), ... reactions, including anaphylaxis can occur in patients receiving these ...
(Date:3/3/2015)... 2015 In March, 1% for the ... kick off a new campaign, “Know Your Source,” which calls ... and ambassadors in their quest for ingredient awareness and better ... of its members and partners, including King Arthur Flour, Good ... to raise awareness for food as an environmental issue, with ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... US Air Purifiers LLC , an ... is pleased to announce that all Rabbit brand air purifiers ... to the west coast port strikes. This news comes just ... , The port strikes, which have caused ... quarter economic growth by as much as 1%, have hindered ...
Breaking Medicine News(10 mins):Health News:Smart sensor and air purifier interconnect to track and trap dust, pollen and dangerous particles in home and workplace air 2Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3
... was halted early after risk of both recurrence and ... -- European researchers report more grim news concerning women ... run the risk of developing breast cancer while taking ... face a higher risk of a recurrence or a ...
... to be published in the American Journal of,Epidemiology, ... publication in the American Journal of Epidemiology, a team ... Michigan found,that women who ate the most fish (more ... pregnancies delivered children with the highest,scores on two cognitive ...
... year when more,than 1.5 million high school and college students ... large quantities of alcohol. Students who,vacation with friends over spring ... home with parents or relatives, according to a report in ... and Drugs., Instead of just telling students not to ...
... HILL, N.C., March 25 Successful brand leaders,know ... crucial and effective,strategies to optimize a product,s lifecycle., ... Promotion in,segmented sectors, and Clinical and Scientific Excellence ... a brand,s success and describes exactly,which costs need ...
... whites, study finds , , TUESDAY, March 25 (HealthDay News) -- ... blacks are much less likely to get colonoscopies than their ... who have an increased chance of developing colon cancer continue ... lack of a doctor referral stood out as the primary ...
... NEW YORK, March 25 For journalists covering,today,s release ... and,Medicare assessing the fiscal health of the government,s two ... budget),the authors of a popular book on the federal ... question: Are America,s leaders so immersed in,short term political ...
Cached Medicine News:Health News:HRT Raises Recurrence Risk Among Breast Cancer Survivors 2Health News:Study: Pregnant Women Who Eat More Fish, Including Canned Tuna, Have Smarter Children 2Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2Health News:Sales and Marketing Effectiveness in Pharmaceutical Companies Increases Brand Performance 2Health News:High-Risk Blacks Less Likely to Get Colonoscopies 2
(Date:3/3/2015)... Mass. , March 3, 2015 Boston Scientific ... Charles J. Dockendorff and Stephen P. MacMillan ... Two current members of the board, Uwe E. Reinhardt ... for re-election at the company,s annual meeting of stockholders in ... was formerly the executive vice president and chief financial officer ...
(Date:3/3/2015)... , March 3, 2015   Surefire ... a prospective clinical trial comparing the Surefire Infusion System ... either primary or metastatic liver cancer, using the ... uptake of embolic agents, and with significantly decreased ... presented today at the Society of Interventional ...
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ... POC Diagnostics Market 2015-2019" report to their offering. ... POC Diagnostics market to grow at a CAGR of ... POC diagnostics are IVD devices and tools used for ... The use of these devices helps in the rapid ...
Breaking Medicine Technology:Boston Scientific Elects Charles J. Dockendorff And Stephen P. MacMillan To Board Of Directors 2Clinical Trial Comparing the Surefire Infusion Device to an End Hole Catheter Finds Surefire Increases Tumor Uptake and Decreases Non-Target Embolization In Every Patient, Multiple Liver Cancer Types 2Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2
... 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a developer ... Eliezer Zomer, Ph.D., Executive Vice,President, Product Development ... Advanced Solid Tumors of,5-FU with an Admixture ... of Oncodevelopmental Biology and Medicine,(ISOBM) Conference to ...
... Investigative Dermatology, FREEPORT, N.Y., May 16, 2007 ... clinical data that indicates,that OCTN-1 skin cells ... L-ergothioneine (EGT) as a protector against oxidative,damage, ... more powerful and,efficient antioxidant than idebenone, scavenging ...
Cached Medicine Technology:Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 2Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 3Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 5AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: